25 April 2019 ORYZON to present vafidemstat efficacy data at the 7th World Congress on ADHD in Lisbon
15 April 2019 ORYZON to present further REIMAGINE efficacy data with vafidemstat at the 7th World Congress on ADHD in Lisbon
8 April 2019 ORYZON to present first in human efficacy data with Vafidemstat at the 27th European Congress of Psychiatry in Warsaw
20 March 2019 Oryzon to present latest advances of Vafidemstat at Oppenheimer’s 29th Annual Healthcare Conference
11 March 2019 ORYZON announces FDA Approval of IND for ETHERAL, a Phase IIa trial of the epigenetic drug Vafidemstat in Patients with mild to moderate Alzheimer’s disease
1 March 2019 New paper relevant for the optimal development of drugs targeting LSD1 published by ORYZON
15 February 2019 ORYZON Reports Financial Results and Corporate Update for the 4thQuarter and Year Ended December 31, 2018